D. C. Bode

发表

In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors.

G. M. Briggs, A. Treasurywala, C. Weigelt, 1996, Biochemical pharmacology.

Cytochrome-P450 induction and conjugated metabolism in primary human hepatocytes after cryopreservation

Chuang Lu, Albert P. Li, D. C. Bode, 1997 .

Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.

P. Pratt, R. Dundore, K. N. Jackson, 1992, European journal of pharmacology.

Adenosine 3',5'-cyclic monophosphate attenuates neutrophil-mediated increase in endothelial permeability.

A. Malik, D. C. Bode, A. Siflinger‐Birnboim, 1993, The American journal of physiology.

Comparison of urinary desmosine excretion in patients with chronic obstructive pulmonary disease or cystic fibrosis.

D. C. Bode, P. Silver, L. Hamel, 2000, Pulmonary pharmacology & therapeutics.

Enrichment and analysis of desmosine and isodesmosine in biological fluids.

D. C. Bode, E. Pagani, W. R. Cumiskey, 1995, Journal of chromatography. B, Biomedical applications.

Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue.

L. Brunton, J. Kanter, D. C. Bode, 1991, Circulation research.

Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats.

R. Dundore, D. C. Bode, P. Silver, 1993, European journal of pharmacology.

Novel and potent adenosine 3',5'-cyclic phosphate phosphodiesterase III inhibitors: thiazolo[4,5-b][1,6]naphthyridin-2-ones.

R. Bentley, M. Connell, P. Pennock, 1995, Journal of medicinal chemistry.

Hypothermic storage of isolated human hepatocytes: a comparison between University of Wisconsin solution and a hypothermosol platform

D. C. Bode, A. Ostrowska, R. V. Buskirk, 2009, Archives of Toxicology.

Effects of chronic exposure to ethanol on the physical and functional properties of the plasma membrane of S49 lymphoma cells.

P. Molinoff, D. C. Bode, 1988, Biochemistry.

Relationship between ethanol-induced alterations in fluorescence anisotropy and adenylate cyclase activity.

P. Molinoff, R. Rabin, D. C. Bode, 1986, Biochemical pharmacology.

Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I)

D. Hlasta, D. C. Bode, P. Silver, 1997 .

Muscarinic receptor subtypes in human and rabbit bladder

A. Wein, R. Levin, D. C. Bode, 1987 .

Distinct profiles of phosphodiesterase isozymes in cultured cells derived from nonpigmented and pigmented ocular ciliary epithelium.

M. Wax, D. C. Bode, L. Hamel, 1993, The Journal of pharmacology and experimental therapeutics.

Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5.

E. Bacon, R. Dundore, D. C. Bode, 1998, European journal of pharmacology.

Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.

G. Y. Lesher, E. Bacon, R. Dundore, 1994, The Journal of pharmacology and experimental therapeutics.

Effects of ethanol in vitro on the beta adrenergic receptor-coupled adenylate cyclase system.

P. Molinoff, D. C. Bode, 1988, The Journal of pharmacology and experimental therapeutics.

Investigation of Functional and Morphological Integrity of Freshly Isolated and Cryopreserved Human Hepatocytes

B. Bilir, D. C. Bode, A. Ostrowska, 2004, Cell and Tissue Banking.

Resolution of soluble rat cardiac phosphodiesterases by high performance liquid chromatography.

L. Brunton, J. Kanter, D. C. Bode, 1988, Second messengers and phosphoproteins.

Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.

R. Bentley, M. Connell, G. Y. Lesher, 1992, Journal of medicinal chemistry.

Post-receptor modulation of the effects of cyclic AMP in isolated cardiac myocytes

L. Brunton, D. C. Bode, 1988, Molecular and Cellular Biochemistry.